Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PDA1
MCID: PTN014
MIFTS: 61

Patent Ductus Arteriosus 1 (PDA1)

Categories: Blood diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Patent Ductus Arteriosus 1

About this section

MalaCards integrated aliases for Patent Ductus Arteriosus 1:

Name: Patent Ductus Arteriosus 1 58 30
Patent Ductus Arteriosus 58 12 77 54 38 6 15 64
Patent Ductus Arteriosus, Susceptibility to 58 13
Ductus Arteriosus, Patent 12 45
Pda1 58 54
Pda 58 54
Patent Ductus Arteriosus - Persisting Type 74
Patent Ductus Arteriosus Familial 54
Patency of the Ductus Arteriosus 54
Ductus Arteriosus Patent 56
Patent Ductus Botalli 12

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
patent ductus arteriosus 1:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases Fetal diseases
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:13832
OMIM 58 607411
KEGG 38 H01630
ICD9CM 36 747.0
MeSH 45 D004374
NCIt 51 C84492
SNOMED-CT 69 83330001
ICD10 34 Q25.0
MedGen 43 C4282128
SNOMED-CT via HPO 70 258211005
Sources

Summaries for Patent Ductus Arteriosus 1

About this section
OMIM : 58 Persistent patency of the ductus arteriosus, or patent ductus arteriosus (PDA), is the second most common congenital heart disease, affecting approximately 1 in 1,600 to 5,000 live births in the U.S. (Mitchell et al., 1971). In fetal life, the ductus arteriosus, a muscular artery, shunts blood from the pulmonary artery to the aorta, bypassing the lungs. Its abrupt closure at birth establishes the mature circulatory pattern and represents a dramatic example of vascular remodeling. Failure of this normal process results in persistent PDA, which left untreated can result in pulmonary hypertension and heart failure. Closure of the ductus is a complex process. Aspects of this process are regulated by oxygen tension and a decrease in levels of hormones such as prostaglandin E2. PDA occurring in preterm infants often closes spontaneously or in response to inhibitors of prostaglandin biosynthesis (Ramsay et al., 1987). Term PDA typically has not been regarded as a genetic disorder, because it most often occurs sporadically. Nonetheless, term PDA recurs among 5% of sibs of PDA cases (Polani and Campbell, 1960; Lamy et al., 1957), suggesting a genetic component to disease pathogenesis that has typically been presumed to be multifactorial. That single genes can influence this trait has been demonstrated by a mouse model of PDA resulting from disruption of the prostaglandin E2 receptor (Nguyen et al., 1997) and by rare syndromic forms of PDA such as Char syndrome (169100), an autosomal dominant disorder caused by mutations in the transcription factor TFAP2B (601601) (Mani et al., 2002). (607411)

MalaCards based summary : Patent Ductus Arteriosus 1, also known as patent ductus arteriosus, is related to char syndrome and aortic valve disease 1. An important gene associated with Patent Ductus Arteriosus 1 is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are Vascular smooth muscle contraction and Heart Development. The drugs Ibuprofen and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and kidney, and related phenotypes are patent ductus arteriosus and cardiovascular system

PubMed Health : 64 About patent ductus arteriosus: Patent ductus arteriosus (PDA) is a heart problem that affects some babies soon after birth. In PDA, abnormal blood flow occurs between two of the major arteries connected to the heart. These arteries are the aorta and the pulmonary (PULL-mun-ary) artery.Before birth, these arteries are connected by a blood vessel called the ductus arteriosus. This blood vessel is a vital part of fetal blood circulation.Within minutes or up to a few days after birth, the ductus arteriosus closes. This change is normal in newborns.In some babies, however, the ductus arteriosus remains open (patent). The opening allows oxygen-rich blood from the aorta to mix with oxygen-poor blood from the pulmonary artery. This can strain the heart and increase blood pressure in the lung arteries.

Wikipedia : 77 Patent ductus arteriosus (PDA) is a condition wherein the ductus arteriosus fails to close after... more...

Sources

Related Diseases for Patent Ductus Arteriosus 1

About this section

Diseases in the Patent Ductus Arteriosus 1 family:

Patent Ductus Arteriosus 2 Patent Ductus Arteriosus 3

Diseases related to Patent Ductus Arteriosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 char syndrome 31.9 ACTA2 NKX2-5 TFAP2A TFAP2B
2 aortic valve disease 1 31.1 ACTA2 NKX2-5 NPPB
3 pulmonary valve stenosis 30.9 GATA4 PTPN11
4 patent foramen ovale 30.8 GATA4 GATA6 NKX2-5 PTPN11 TLL1
5 tetralogy of fallot 30.7 GATA4 GATA6 NKX2-5 NPPB PTPN11
6 atrioventricular septal defect 30.6 GATA4 GATA6 NKX2-5
7 double outlet right ventricle 30.4 GATA4 GATA6 NKX2-5
8 ventricular septal defect 29.9 GATA4 GATA6 NKX2-5 NPPB
9 atrial heart septal defect 29.9 GATA4 GATA6 NKX2-5 TLL1
10 heart disease 29.4 FLNA GATA4 GATA6 NKX2-5 NPPB PTPN11
11 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 12.7
12 intestinal pseudoobstruction with patent ductus arteriosus and natal teeth 12.5
13 congenital patent ductus arteriosus aneurysm 12.5
14 pulmonary artery coming from patent ductus arteriosus 12.5
15 multisystemic smooth muscle dysfunction syndrome 12.4
16 aortic aneurysm, familial thoracic 4 12.1
17 heterotaxy, visceral, 1, x-linked 11.9
18 fontaine progeroid syndrome 11.9
19 eisenmenger syndrome 11.8
20 femoral-facial syndrome 11.7
21 cantu syndrome 11.6
22 microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome 11.6
23 ramos arroyo clark syndrome 11.6
24 right pulmonary artery, anomalous origin of, familial 11.5
25 natal teeth, intestinal pseudoobstruction and patent ductus 11.5
26 premature closure of the arterial duct 11.5
27 hypertelorism, teebi type 11.4
28 mcdonough syndrome 11.4
29 hypertrophic osteoarthropathy, primary, autosomal recessive, 1 11.4
30 periventricular nodular heterotopia 1 11.4
31 heart defects, congenital, and other congenital anomalies 11.4
32 axenfeld-rieger syndrome, type 3 11.4
33 nephronophthisis 16 11.4
34 congenital heart defects, multiple types, 4 11.4
35 nephronophthisis 20 11.4
36 congenital heart defects, multiple types, 5 11.4
37 cardiac, facial, and digital anomalies with developmental delay 11.4
38 hypoplastic left heart syndrome 11.4
39 chromosome 15, trisomy mosaicism 11.4
40 manouvrier syndrome 11.4
41 mcgillivray syndrome 11.4
42 pulmonary valve agenesis-intact ventricular septum-persistent ductus arteriosus syndrome 11.1
43 patent ductus arteriosus 2 11.1
44 patent ductus arteriosus 3 11.1
45 coarctation of aorta 10.6
46 mitral valve stenosis 10.6
47 aortic arch interruption 10.6
48 enterocolitis 10.6
49 pulmonic stenosis 10.6
50 perinatal necrotizing enterocolitis 10.6

Graphical network of the top 20 diseases related to Patent Ductus Arteriosus 1:



Diseases related to Patent Ductus Arteriosus 1
Sources

Symptoms & Phenotypes for Patent Ductus Arteriosus 1

About this section

Human phenotypes related to Patent Ductus Arteriosus 1:

33
# Description HPO Frequency HPO Source Accession
1 patent ductus arteriosus 33 HP:0001643

Symptoms via clinical synopsis from OMIM:

58
Cardiovascular Vascular:
patent ductus arteriosus

Clinical features from OMIM:

607411

MGI Mouse Phenotypes related to Patent Ductus Arteriosus 1:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 ACTA2 FLNA GATA4 GATA6 MYH11 NKX2-5
2 cellular MP:0005384 10.21 FLNA GATA4 GATA6 INPP5E MYH11 NKX2-5
3 growth/size/body region MP:0005378 10.2 AVPR2 FLNA GATA4 GATA6 INPP5E MYH11
4 homeostasis/metabolism MP:0005376 10.18 AVPR2 FLNA GATA4 GATA6 MYH11 NKX2-5
5 hematopoietic system MP:0005397 10.13 AVPR2 FLNA GATA4 GATA6 NKX2-5 PTGER4
6 digestive/alimentary MP:0005381 10.1 FLNA GATA4 INPP5E MYH11 NKX2-5 PTPN11
7 embryo MP:0005380 10.08 GATA4 GATA6 INPP5E NKX2-5 NSD1 PRDM6
8 integument MP:0010771 10.07 AVPR2 GATA4 MYH11 NKX2-5 PRDM6 PTGER4
9 mortality/aging MP:0010768 10.03 AVPR2 FLNA GATA4 GATA6 INPP5E MYH11
10 limbs/digits/tail MP:0005371 9.87 GATA4 GATA6 INPP5E PTPN11 TFAP2A TFAP2B
11 liver/biliary system MP:0005370 9.8 FLNA GATA4 GATA6 PTGER4 PTPN11 TLL1
12 muscle MP:0005369 9.61 ACTA2 GATA4 GATA6 MYH11 NKX2-5 PTGER4
13 respiratory system MP:0005388 9.32 FLNA GATA4 GATA6 MYH11 NKX2-5 PRDM6
Sources

Drugs & Therapeutics for Patent Ductus Arteriosus 1

About this section

PubMedHealth treatment related to Patent Ductus Arteriosus 1: 64

Patent ductus arteriosus (PDA) is treated with medicines, catheter-based procedures, and surgery. The goal of treatment is to close the PDA. Closure will help prevent complications and reverse the effects of increased blood volume.Small PDAs often close without treatment. For full-term infants, treatment is needed if the PDA is large or causing health problems. For premature infants, treatment is needed if the PDA is causing breathing problems or heart problems.Talk with your child's doctor about treatment options and how your family prefers to handle treatment decisions.

Drugs for Patent Ductus Arteriosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15687-27-1 3672
2
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 103-90-2 1983
3
Indomethacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53-86-1 3715
4 Poractant alfa Approved Phase 4,Phase 3,Not Applicable 129069-19-8
5 Beractant Approved Phase 4,Not Applicable 108778-82-1
6
Progesterone Approved, Vet_approved Phase 4,Phase 3 57-83-0 5994
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
9
Iodine Approved, Investigational Phase 4 7553-56-2 807
10 Antipyretics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
13 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
18 Pulmonary Surfactants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Tocolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
20 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 3
22 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
23 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
24 Progestins Phase 4,Phase 3
25 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
27 Hormone Antagonists Phase 4,Phase 3,Phase 2
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
29 Cytochrome P-450 CYP2C19 Inhibitors Phase 4
30 Steroid Synthesis Inhibitors Phase 4
31 Antifungal Agents Phase 4
32 Nutrients Phase 4,Phase 3
33 Micronutrients Phase 4,Phase 3
34 Anti-Infective Agents, Local Phase 4
35 Trace Elements Phase 4,Phase 3
36 cadexomer iodine Phase 4
37 Vitamins Phase 4,Phase 3
38
Clarithromycin Approved Phase 3 81103-11-9 84029
39
tannic acid Approved Phase 3,Phase 2,Not Applicable 1401-55-4
40
Benzocaine Approved, Investigational Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
41
Fenoldopam Approved Phase 2, Phase 3 67227-56-9, 67227-57-0 3341
42
Dopamine Approved Phase 2, Phase 3,Not Applicable 62-31-7, 51-61-6 681
43
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
44
Dexmedetomidine Approved, Vet_approved Phase 3 113775-47-6 5311068 68602
45
Ethanol Approved Phase 3 64-17-5 702
46
Benzyl alcohol Approved Phase 3 100-51-6 244
47
Caffeine Approved Phase 3 58-08-2 2519
48
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
49
Atosiban Approved, Investigational Phase 3,Phase 2 90779-69-4
50
Azithromycin Approved Phase 3,Phase 2 83905-01-5 447043 55185

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants Unknown status NCT01544972 Phase 4 Oral paracetamol;Oral ibuprofen
2 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
3 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
4 Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Completed NCT01536158 Phase 4 Oral paracetamol;Oral ibuprofen
5 Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies Withdrawn NCT00470743 Phase 4 Ibuprofen;Indomethacin
6 Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Completed NCT00642330 Phase 4 oral ibuprofen;intravenous ibuprofen
7 Paracetamol Versus Ibuprofen for PDA Closure Active, not recruiting NCT03265782 Phase 4 ibuprofen;paracetamol
8 Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Terminated NCT00961753 Phase 4 optimized ibuprofen;Standard Ibuprofen
9 Ibuprofen and Renal Function in Premature Infants Completed NCT00217191 Phase 4 Ibuprofen
10 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
11 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
12 Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor Recruiting NCT02430233 Phase 4 micronized progesterone 400 mg (Utrogestan)
13 Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants Completed NCT02079298 Phase 4 Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
14 A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years Completed NCT00638092 Phase 4 sodium iodide;Sodium Chloride
15 Personalized vs Standardized PN for Preterm Infants >1250g Not yet recruiting NCT03693287 Phase 4 Standardized-parenteral nutrition (S-PN);Personalized-parenteral nutrition (P-PN)
16 TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence Recruiting NCT02621645 Phase 4
17 Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants Unknown status NCT02002741 Phase 2, Phase 3 Paracetamol;Placebo
18 Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
19 An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Terminated NCT00750581 Phase 2, Phase 3 Indomethacin
20 Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus Completed NCT01593163 Phase 3 Ibuprofen EchoG;Standard ibuprofen treatment
21 Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Completed NCT03022253 Phase 3 Paracetamol;Ibuprofen
22 Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Active, not recruiting NCT01630278 Phase 3 Ibuprofen;Placebo
23 High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant Completed NCT01243996 Phase 2, Phase 3 Ibuprofen
24 Alternative Paracetamol Treatments for the Neonate With a hsPDA Not yet recruiting NCT03604796 Phase 2, Phase 3 Rectal Solution;Intravenous Infusion
25 Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA Completed NCT00440804 Phase 3 ibuprofen l-lysine iv solution (NeoProfen (R) )
26 Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Completed NCT00485160 Phase 3 Continuous indomethacin;ibuprofen
27 Acetaminophen vs Indomethacin in Treating hsPDA Recruiting NCT03537144 Phase 3 Indomethacin;Acetaminophen
28 Management of the PDA Trial Recruiting NCT03456336 Phase 3
29 Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants. Recruiting NCT02056223 Phase 2, Phase 3 Intravenous paracetamol;Intravenous ibuprofen
30 Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Recruiting NCT02620761 Phase 2, Phase 3 Fenoldopam;0.9%NS
31 Management of Patent Ductus in Premature Infants Completed NCT00000494 Phase 3 indomethacin
32 Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Completed NCT00009646 Phase 3 indomethacin;Indomethacin;Placebo
33 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia Completed NCT01306227 Phase 3 L-Thyroxine;water
34 Effects of Fat-soluble Vitamins Supplementation on Common Complications and Neural Development in Very Low Birth Weight Infants Recruiting NCT03876704 Phase 3 High dose of fat-Soluble Vitamin;Conventional dose of fat-Soluble Vitamin
35 The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease Completed NCT00480740 Phase 3 Dexmedetomidine
36 Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Recruiting NCT01755728 Phase 3 Paracetamol;Ibuprofen
37 Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation Terminated NCT01306240 Phase 3
38 RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix Terminated NCT00439374 Phase 3 17 alpha-hydroxyprogesterone caproate
39 Comparison of Two Flow Rates of HHHFNC to Prevent Extubation Failure in Preterm Infants Recruiting NCT02681315 Phase 3
40 NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome) Completed NCT02259400 Phase 2, Phase 3
41 Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth Recruiting NCT02897076 Phase 3 betamethasone 24 mg;12mg betamethasone +placebo
42 Canadian Oxygen Trial (COT) Completed NCT00637169 Phase 3
43 Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Completed NCT00114543 Phase 3
44 Inositol to Reduce Retinopathy of Prematurity Terminated NCT01954082 Phase 3 myo-Inositol 5% Injection;Placebo
45 Cycled Phototherapy Not yet recruiting NCT03927833 Phase 3
46 A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor Terminated NCT02377466 Phase 3 Retosiban IV infusion;Placebo IV infusion
47 A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour Terminated NCT02292771 Phase 3 Retosiban;Atosiban;Placebo matching retosiban;Placebo matching atosiban
48 TINN2: Treat Infection in NeoNates 2 Withdrawn NCT02282176 Phase 3 Azithromycin;Placebo
49 Magnesium Sulphate for Preterm Birth (MASP Study) Active, not recruiting NCT01492608 Phase 3 Magnesium sulphate
50 Persistent Pulmonary Hypertension of the Newborn Terminated NCT01389856 Phase 3 Bosentan;Matching placebo

Search NIH Clinical Center for Patent Ductus Arteriosus 1

Cochrane evidence based reviews: ductus arteriosus, patent

Sources

Genetic Tests for Patent Ductus Arteriosus 1

About this section

Genetic tests related to Patent Ductus Arteriosus 1:

# Genetic test Affiliating Genes
1 Patent Ductus Arteriosus 1 30
Sources

Anatomical Context for Patent Ductus Arteriosus 1

About this section

MalaCards organs/tissues related to Patent Ductus Arteriosus 1:

42
Heart, Brain, Kidney, Smooth Muscle, Bone, Cervix, Lung
Sources

Publications for Patent Ductus Arteriosus 1

About this section

Articles related to Patent Ductus Arteriosus 1:

(show top 50) (show all 3049)
# Title Authors Year
1
Endovascular therapy of a giant renal artery aneurysm combined with high-flow renal arteriovenous fistula using a patent ductus arteriosus occluder. ( 30802564 )
2019
2
Hemodynamically significant patent ductus arteriosus and the development of bronchopulmonary dysplasia. ( 30343505 )
2019
3
A case report of interrupted aortic arch without patent ductus arteriosus and with double-outlet right ventricle. ( 30767265 )
2019
4
Effect of patent ductus arteriosus on pulmonary vascular disease. ( 30811787 )
2019
5
Is high platelet distribution width in the first hours of life can predict hemodynamically significant patent ductus arteriosus in preterm newborns? ( 30318943 )
2019
6
A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. ( 30323322 )
2019
7
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. ( 30340932 )
2019
8
Predictors of Respiratory Improvement 1 Week after Ligation of Patent Ductus Arteriosus in Preterm Infants. ( 30348438 )
2019
9
Surgical ligation of patent ductus arteriosus in a dorper sheep. ( 30365170 )
2019
10
Correction: A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. ( 30429580 )
2019
11
New Patent Ductus Arteriosus Closure Devices and Techniques. ( 30449419 )
2019
12
A Patient-Specific Hollow Three-Dimensional Model for Simulating Percutaneous Occlusion of Patent Ductus Arteriosus. ( 30464122 )
2019
13
Altered plasma proteins released from platelets and endothelial cells are associated with human patent ductus arteriosus. ( 30480800 )
2019
14
Results of the combined U.S. multicenter postapproval study of the Nit-Occlud PDA device for percutaneous closure of patent ductus arteriosus. ( 30511498 )
2019
15
Development of tissue Doppler-derived predictors of hemodynamically significant patent ductus arteriosus and the ability to incorporate it in targeted neonatal echocardiography protocol. ( 30618483 )
2019
16
Acute Aortic Dissection as a Rare Complication of Percutaneous Closure Using the Amplatzer Vascular Plug II for a Tubular and Enlarged Patent Ductus Arteriosus in an Elderly Patient. ( 30621984 )
2019
17
Wide Pulse Pressure Is Not Associated with Patent Ductus Arteriosus in the First Week of Life. ( 30646420 )
2019
18
Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants. ( 30664589 )
2019
19
Successful Percutaneous Treatment of an Embolized Patent Ductus Arteriosus Occluder Device. ( 30691353 )
2019
20
Patent ductus arteriosus is associated with acute kidney injury in the preterm infant. ( 30706125 )
2019
21
Understanding the Pathophysiology, Implications, and Treatment Options of Patent Ductus Arteriosus in the Neonatal Population. ( 30720481 )
2019
22
Does Postmenstrual Age Affect Medical Patent Ductus Arteriosus Treatment Success in Preterm Infants? ( 30726998 )
2019
23
Urinary acute kidney injury biomarkers in very low-birth-weight infants on indomethacin for patent ductus arteriosus. ( 30745571 )
2019
24
Early haemodynamically significant patent ductus arteriosus does not predict future persistence in extremely preterm infants. ( 30748032 )
2019
25
Patent ductus arteriosus and small for gestational age infants: Treatment approaches and outcomes. ( 30771741 )
2019
26
Classification scheme for ductal morphology in cyanotic patients with ductal dependent pulmonary blood flow and association with outcomes of patent ductus arteriosus stenting. ( 30790426 )
2019
27
A pictorial view of the three-dimensional representation and comparative two-dimensional image orientation derived from computed tomography angiography in a dog with a patent ductus arteriosus. ( 30797443 )
2019
28
Intrauterine Growth Restriction and Patent Ductus Arteriosus in Very and Extremely Preterm Infants: A Systematic Review and Meta-Analysis. ( 30800098 )
2019
29
Effect of patent ductus arteriosus on the heart in preterm infants. ( 30811789 )
2019
30
Overview of transcatheter patent ductus arteriosus closure in preterm infants. ( 30811790 )
2019
31
A comprehensive program for preterm infants with patent ductus arteriosus. ( 30811791 )
2019
32
Percutaneous closure of the patent ductus arteriosus: opportunities moving forward. ( 30811795 )
2019
33
Echocardiography of the patent ductus arteriosus in premature infant. ( 30811799 )
2019
34
Echocardiographic guidance for transcatheter patent ductus arteriosus closure in extremely low birth weight infants. ( 30811801 )
2019
35
Blalock-Taussig shunt versus patent ductus arteriosus stent as first palliation for ductal-dependent pulmonary circulation lesions: A review of the literature. ( 30811802 )
2019
36
Practice variation in the management of patent ductus arteriosus in extremely low birth weight infants in the United States: Survey results among cardiologists and neonatologists. ( 30811803 )
2019
37
Surgical management of patent ductus arteriosus. ( 30811804 )
2019
38
Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). ( 30850756 )
2019
39
Cocoon devices for transcatheter closure of atrial septal defect and patent ductus arteriosus in children: Single center experience. ( 30855458 )
2019
40
Safety of an improved patent ductus arteriosus occluder for transcatheter closure of perimembranous ventricular septal defects with abnormally attached tricuspid chordae tendineae. ( 30863756 )
2019
41
Relation of shunt index with the patent ductus arteriosus among preterm infants under 30 weeks or 1500 g. ( 30909769 )
2019
42
Cardiac catheterisation for closure of patent ductus arteriosus. ( 30928352 )
2019
43
Anticipatory perioperative management for patent ductus arteriosus surgery: Understanding postligation cardiac syndrome. ( 30945807 )
2019
44
Acute ascending aortic dissection due to transcatheter patent ductus arteriosus closure in the elderly: An extremely rare complication of transcatheter patent ductus arteriosus closure. ( 30949247 )
2019
45
Indexed patent ductus arteriosus size as the prime predictor of post device closure left ventricular dysfunction: does it have any competitors? ( 30956182 )
2019
46
Reply to the letter to the editor by Garg "Indexed patent ductus arteriosus size as the prime predictor of post device closure left ventricular dysfunction: does it have any competitors?" ( 30956183 )
2019
47
Understanding the pathobiology in patent ductus arteriosus in prematurity-beyond prostaglandins and oxygen. ( 30965358 )
2019
48
Fluid restriction negatively affects energy intake and growth in very low birth weight infants with haemodynamically significant patent ductus arteriosus. ( 30980416 )
2019
49
Heart failure in a post-partum patient with patent ductus arteriosus. ( 30983448 )
2019
50
Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. ( 30988681 )
2019
Sources

Variations for Patent Ductus Arteriosus 1

About this section

ClinVar genetic disease variations for Patent Ductus Arteriosus 1:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 INPP5E NM_019892.4(INPP5E): c.1132C> T (p.Arg378Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121918130 GRCh37 Chromosome 9, 139327634: 139327634
2 INPP5E NM_019892.4(INPP5E): c.1132C> T (p.Arg378Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121918130 GRCh38 Chromosome 9, 136433182: 136433182
3 TNFRSF13B NM_012452.2(TNFRSF13B): c.310T> C (p.Cys104Arg) single nucleotide variant risk factor rs34557412 GRCh37 Chromosome 17, 16852187: 16852187
4 TNFRSF13B NM_012452.2(TNFRSF13B): c.310T> C (p.Cys104Arg) single nucleotide variant risk factor rs34557412 GRCh38 Chromosome 17, 16948873: 16948873
5 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh37 Chromosome 12, 112888168: 112888168
6 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh38 Chromosome 12, 112450364: 112450364
7 VANGL1 NM_138959.2(VANGL1): c.523C> T (p.Arg175Trp) single nucleotide variant Uncertain significance rs142594314 GRCh37 Chromosome 1, 116206600: 116206600
8 VANGL1 NM_138959.2(VANGL1): c.523C> T (p.Arg175Trp) single nucleotide variant Uncertain significance rs142594314 GRCh38 Chromosome 1, 115663979: 115663979
9 46;XX;ins(5;6)(p13;p24p25)dn Translocation Pathogenic
10 46;XY;inv(6)(p22q13)dn inversion Pathogenic
11 46;XX;inv(7)(q21.2q34) inversion Likely pathogenic
12 46;XY;t(2;14)(p22;q24.3)dn Translocation Likely pathogenic
13 46;XX;ins(2;9)(q24.3;p22.1p24.3)dn Translocation Pathogenic
14 HYDIN NM_001270974.2(HYDIN): c.10816G> T (p.Gly3606Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome 16, 70908340: 70908340
15 HYDIN NM_001270974.2(HYDIN): c.10816G> T (p.Gly3606Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome 16, 70874437: 70874437
16 HYDIN NM_001270974.2(HYDIN): c.6631G> A (p.Asp2211Asn) single nucleotide variant Uncertain significance GRCh37 Chromosome 16, 70977753: 70977753
17 HYDIN NM_001270974.2(HYDIN): c.6631G> A (p.Asp2211Asn) single nucleotide variant Uncertain significance GRCh38 Chromosome 16, 70943850: 70943850
Sources

Expression for Patent Ductus Arteriosus 1

About this section
Search GEO for disease gene expression data for Patent Ductus Arteriosus 1.
Sources

Pathways for Patent Ductus Arteriosus 1

About this section

Pathways related to Patent Ductus Arteriosus 1 according to KEGG:

38
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270

Pathways related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Heart Development 1
10.59 GATA4 GATA6 NKX2-5 PTPN11
2
Cardiomyocyte Differentiation through BMP Receptors 65
10.47 GATA4 NKX2-5 NPPB
3
HOP Signaling 65
9.93 GATA4 NKX2-5
Sources

GO Terms for Patent Ductus Arteriosus 1

About this section

Biological processes related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 FLNA GATA6 NKX2-5 TFAP2A TFAP2B
2 negative regulation of transcription, DNA-templated GO:0045892 9.85 GATA6 NKX2-5 PRDM6 TFAP2A TFAP2B
3 transcription by RNA polymerase II GO:0006366 9.69 GATA4 GATA6 TFAP2B
4 retina layer formation GO:0010842 9.52 TFAP2A TFAP2B
5 positive regulation of transcription, DNA-templated GO:0045893 9.5 ACTA2 GATA4 GATA6 NKX2-5 NSD1 TFAP2A
6 cardiac muscle tissue development GO:0048738 9.49 GATA6 NKX2-5
7 positive regulation of urine volume GO:0035810 9.43 NPPB TFAP2B
8 atrial septum morphogenesis GO:0060413 9.4 GATA4 NKX2-5
9 heart development GO:0007507 9.37 NKX2-5 PTPN11
10 cardiac muscle cell differentiation GO:0055007 9.33 GATA4 GATA6 NKX2-5
11 cardiac ventricle morphogenesis GO:0003208 9.32 GATA4 NKX2-5
12 intestinal epithelial cell differentiation GO:0060575 9.26 GATA4 GATA6
13 positive regulation of cardioblast differentiation GO:0051891 8.8 GATA4 GATA6 NKX2-5

Molecular functions related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.98 GATA4 GATA6 NKX2-5 PRDM6 TFAP2A TFAP2B
2 DNA-binding transcription factor activity GO:0003700 9.85 GATA4 GATA6 NKX2-5 TFAP2A TFAP2B ZNF213
3 transcription factor binding GO:0008134 9.76 FLNA GATA4 GATA6 NKX2-5
4 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.71 GATA4 PRDM6 TFAP2A TFAP2B
5 chromatin binding GO:0003682 9.65 GATA6 NKX2-5 NSD1 TFAP2A TFAP2B
6 sequence-specific DNA binding GO:0043565 9.63 GATA4 GATA6 NKX2-5 PRDM6 TFAP2A TFAP2B
7 transcription regulatory region DNA binding GO:0044212 9.62 GATA4 GATA6 NKX2-5 TFAP2A
8 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.43 GATA4 GATA6 NKX2-5 NSD1 TFAP2A TFAP2B
9 enhancer sequence-specific DNA binding GO:0001158 8.62 GATA4 TFAP2B
Sources

Sources for Patent Ductus Arteriosus 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....